R&D 

Copyright(c)2017 Qilu Pharmaceutical Co., Ltd. 鲁ICP备06006222号 Headquarter Address: 243 Gong Ye Bei Road, Jinan, Shandong 250100, CHINA

PRODUCTS

MANUFACTURING

NEWS

CONTACT US

ABOUT US

Qilu King-Phar successfully passes the US FDA inspection with no 483 observations

Classification:
Company news
Author:
QILU PHARMACEUTICAL
Source:
QILU PHARMACEUTICAL
Release time:
2017/04/19 00:00
Page view
[Abstract]:
March 23, Qilu Pharmaceutical announces that its subsidiary King-Phar Pharmaceutical successfully has passed the US FDA inspection with no 483 observations for the third time.

March 23, Qilu Pharmaceutical announces that its subsidiary King-Phar Pharmaceutical successfully has passed the US FDA inspection with no 483 observations for the third time.

Many aspects including material management, production management, quality management, laboratory management and packaging system are involved in this inspection and the performance of cGMP is highly praised by the auditor.

‘One millionth of the manufacturer is 100% of the patients’.  Qilu Pharmaceutical has always been attaching great importance to the product quality and the quality system is strictly constructed to be geared to international standards. With the aim of exploring the international high-end markets, Qilu Pharmaceutical will continue adhering to the normalization for high standard of the production and quality management in the future,

NEWS